Long noncoding RNA EGOT negatively affects the antiviral response and favors HCV replication

Elena Carnero1,†, Marina Barriocanal1,†, Celia Prior1, Juan Pablo Unfried1, Victor Segura2, Elizabeth Guruceaga2, Mónica Enguita1, Cristian Smerdou1, Pablo Gastaminza3 & Puri Fortes1,*

Abstract

The role of long noncoding RNAs (lncRNAs) in viral infection is poorly studied. We have identified hepatitis C virus (HCV)-stimulated lncRNAs (CSRs) by transcriptome analysis. Interestingly, two of these CSRs (PVT1 and UCA1) play relevant roles in tumorigenesis, providing a novel link between HCV infection and development of liver tumors. Expression of some CSRs seems induced directly by HCV, while others are upregulated by the antiviral response against the virus. In fact, activation of pathogen sensors induces the expression of CSRs3/EGOT. RIG-I and the RNA-activated kinase PKR sense HCV RNA, activate NF-κB and upregulate EGOT. EGOT is increased in the liver of patients infected with HCV and after infection with influenza or Semliki Forest virus (SFV). Genome-wide guilt-by-association studies predict that EGOT may function as a negative regulator of the antiviral pathway. Accordingly, EGOT depletion increases the expression of several interferon-stimulated genes and leads to decreased replication of HCV and SFV. Our results suggest that EGOT is a lncRNA induced after infection that increases viral replication by antagonizing the antiviral response.

Keywords lncRNA; HCV; PKR; SFV

Introduction

The competition between viruses and the immune system is one of the drivers of evolution. During infection, viral factors are sensed by canonical (i.e., RIG-I (retinoic acid-inducible gene 1) or TLRs (Toll-like receptors)) and non-canonical (i.e., PKR) cellular receptors, which trigger activation of NF-κB and interferon regulatory transcription factors (IRFs) leading to expression of type I interferons (IFN) and proinflammatory cytokines [1]. This initiates the cellular antiviral response. Viruses have evolved to express factors that block the antiviral pathways [1]. In turn, the IFN response has evolved to hinder viral infection by affecting the steps required for viral viability. IFN binding to its receptor activates the JAK/STAT pathway and the expression of IFN-stimulated genes (ISGs). Most ISGs are antiviral genes that function to increase cell sensitivity against infections or to block viral entry, replication, translation, stability, or release [1]. Interestingly, some ISGs function as negative regulators of the IFN pathway that limit the duration and strength of the response and are essential in helping the cell to return to homeostasis [1]. Importantly, some of these IFN-induced negative regulators of the IFN pathway have proviral functions [2].

Most ISGs and the cellular factors described as proviral or antiviral are proteins. However, it has been recently shown that the IFN pathway also regulates the expression of several long noncoding RNAs (lncRNAs) [3–6]. This is not surprising, as lncRNAs are thought to be at least as numerous as protein-coding genes and the few lncRNAs studied to date have been shown to play relevant roles in cell proliferation, differentiation, and homeostasis [7]. LncRNAs are transcripts longer than 200 nucleotides with no identifiable protein-coding potential. LncRNA genes are similar to mRNA genes at the chromatin and sequence levels, and they share common mechanisms for transcription and processing. However, lncRNAs are more cell type specific, less abundant, and less conserved than mRNAs. Interestingly, lncRNAs may regulate the expression of distal or neighboring genes by different mechanisms [7].

In line with this, it has been recently shown that many IFN-regulated lncRNA genes function to tune the expression of ISGs located nearby by acting as positive or negative regulators [3–6]. Some of the IFN-induced lncRNAs are also upregulated after viral infection [4,5]. Infection with HIV or influenza virus (Flu), among others, has been shown to alter the expression of cellular lncRNAs [8–10]. Thus, HIV infection increases the expression of NEAT1 and Flu infection increases lncRNA VIN and decreases NRAV. Interestingly, downregulation of NEAT1 increases HIV replication, while downregulation of VIN or NRAV decreases efficiency of Flu

1 Department of Gene Therapy and Hepatology, Center for Applied Medical Research (CIMA) and IdiSNA, Navarra Institute for Health Research, University of Navarra, Pamplona, Spain
2 Bioinformatics Unit, CIMA and IdiSNA, University of Navarra, Pamplona, Spain
3 National Center of Biotechnology CNB/CSIC, Madrid, Spain
*Corresponding author. Tel: +34 948194700; Fax: +34 948194717; E-mail: pfortes@unav.es
†These authors contributed equally to this work
infection. In fact, NRAV is a negative regulator of ISG transcription. This demonstrates that viral infection can alter the expression of cellular lncRNAs with antiviral or proviral functions. However, in general, few virus-regulated lncRNAs have been identified and their function has been poorly studied [11].

In this study, we asked whether the expression of cellular lncRNAs is altered after infection with hepatitis C virus (HCV). HCV is a hepatotropic virus whose infection affects more than 170 million people worldwide and frequently leads to liver cirrhosis and hepatocellular carcinoma [12]. In this study, we examined the transcriptome of control liver cells and cells infected with HCV. Then, we identified lncRNAs whose expression is deregulated in infected cells. The best upregulated candidates have been validated and termed CSRs, after HCV-Stimulated RNAs. Interestingly, several CSRs have been described as oncogenes, providing a link between HCV infection and the development of liver tumors. We show that some of the CSRs are upregulated by treatment with pIC or IFN, indicating that they respond to the antiviral response induced against infection. In fact, stimulation of RIG-I or PKR by HCV activates the expression of CSR32/EGOT. Inhibition of EGOT leads to increased levels of several ISGs and to decreased viral replication. Therefore, EGOT is a proviral lncRNA induced after infection that regulates the antiviral response.

Results

Identification of lncRNAs regulated by HCV

To identify lncRNAs that respond to HCV, we infected HuH7 cells with a moi of 0.3 of the JFH-1 strain of HCV for 6 days. At this time, most of the cells were infected with the virus as evaluated by immunofluorescence against HCV core protein. RNA isolated in most of the cells were infected with the virus as evaluated by analysis of the array showed that many of the coding genes whose expression is altered with a high statistical significance (FC > 2) and that had been previously annotated in public databases (GENCODE, ENSEMBL, RefSeq, GenBank, and Rfam). We selected the probes that showed a significantly altered expression by hybridizing an Agilent array that evaluates expression of 27,958 Entrez genes and 7,419 lncRNAs. Analysis of the array showed that many of the coding genes whose expression is altered with a high statistical significance (B > 0) have already been described as changing levels after HCV infection (Fig 1A and B) [13–15]. These include genes related to immunity and defense (IL8, MX1, IRF1, or members of the CXCL family), genes involved in oxidative stress and detoxification (SOD2 or CYP1A1), and genes involved in cell proliferation, cholesterol synthesis, or fatty acid metabolism. Similar functions were also found by Ingenuity analysis of the data (Appendix Fig S1). We selected the probes that showed a significantly altered expression by HCV infection and that were described in the array as lncRNAs (505 probes with B > 2) (Fig 1C). We excluded from further analysis miss-annotated probes that corresponded to coding genes or seemed to be 3’UTR extensions of coding genes. Seventy-three putative lncRNA genes were identified as upregulated and 82 as downregulated with a log fold change higher than 2 (FC > 2) (Appendix Table S1).

We decided to focus on all those transcripts identified in the array that were significantly upregulated by HCV infection (B > 2 and FC > 2) and that had been previously annotated in public databases (GENCODE, ENSEMBL, RefSeq, GenBank, and Rfam). We called them CSR, from HCV-Stimulated RNAs. We also decided to study CSR30 and CSR33, which had a fold change lower than 2 but corresponded to interesting lncRNAs such as LINC-PINT and TINCR [16,17]. Out of the 35 CSRs, 26 also showed increased levels in RNASeq data of HCV-infected cells compared to controls (Appendix Fig S1; Appendix Table S2). None of the 35 CSRs selected was liver specific according to their analysis using transcriptomes from the Human BodyMap (Appendix Fig S2; https://www.ebi.ac.uk/gxa/experiments/E-MTAB-513).

HCV infection increases the expression of several lncRNAs

To validate the effect of HCV infection on the expression of these 35 CSRs, their levels were evaluated by qRT–PCR in HuH7 cells uninfected or infected with a moi 0.3 of HCV for 6 days. The fold change observed for each candidate in HCV-infected versus non-infected cells is shown in Fig 2A. The expression of most candidates is induced after HCV infection, with the exception of CSR9 and CSR16, which we failed to detect above background levels. Fourteen candidates showed apparent low expression levels by qRT–PCR and were discarded. CSR28 was also discarded as it transcribes SNHG12, a host of small nucleolar RNAs. We opted to focus on the remaining CSRs that displayed the highest upregulation after HCV infection (FC > 7): CSR3, 6, 7, 19, 20, 21, 26, 31, 32, and 34.
Interestingly, some of these lncRNAs are induced several hundred-fold upon infection. To study in more detail the response of these candidates to HCV, we evaluated their expression by qRT–PCR in controls or in cells infected for 12, 24, 48, or 72 h with a moi of 0.3 of HCV JFH-1. The results show that the CSRs increase their expression as infection progresses (Fig 2B).

Analysis of subcellular localization and coding potential of CSRs

Extensive bioinformatic analyses using ORF Finder (NCBI), PhyloCSF, CPAT, and databases such as LNCipedia predict that the selected CSRs are noncoding RNAs (Fig EV1A and B; see Materials and Methods for details [18–23]). Overall, these analyses indicate that (i) all putative ORFs that could be translated are shorter than 100 aa, (ii) bioinformatic analyses predict a low coding probability, and (iii) sequences of the evaluated CSRs are absent from databases related to translation. The only exception is NEURL3/CSR31. Some NEURL3 transcripts could be translated to ORFs longer than 100 aa, have a coding probability above the noncoding threshold, and NEURL3 homologue in rat may encode for an E3 ubiquitin protein ligase. However, NEURL3 is a noncoding pseudogene according to ENCODE. Pseudogenes have a higher possibility of giving false-positive results in programs such as PhyloCSF. The reason for this is that pseudogenes are similar to their parental coding genes, and PhyloCSF evaluates conservation to predict coding capacity. Therefore, further experiments should be performed to determine whether NEURL3 is indeed a coding gene.
The subcellular localization of CSRs was evaluated by qRT–PCR in nuclear or cytoplasmic fractions of HCV-infected cells. As expected, the nuclear lncRNA MALAT1 was preferentially nuclear while the coding GAPDH mRNA was enriched in the cytoplasm (Fig EV1C). Similarly, CSR3, 6, 7, 20, 31, and 34 accumulate preferentially in the cytoplasm while CSR19, 21, 26, and 32 accumulate preferentially in the nucleus. In fact, the nuclear localization of lncRNAs CSR21/PVT1 and the cytoplasmic localization of CSR34/UCA1 have already been reported [24,25]. The preferential nuclear localization of CSR19, 21, 26, and 32, away from the site of translation, together with the bioinformatic analyses, suggests that these CSRs are noncoding RNAs.

Some CSRs respond to the antiviral pathway while others seem to be induced directly by HCV infection

Once we established that most of the selected CSRs are transcripts with poor coding potential induced after infection with HCV, we sought to understand the mechanism of upregulation. CSRs may be upregulated directly by HCV infection or by the antiviral response induced by infection. To determine whether the IFN pathway could affect CSR expression, we treated HuH7 cells with high doses (10,000 U/ml) of IFNα2 for 3 days and compared the expression of the CSRs in IFN-treated versus untreated or HCV-infected cells. Under these conditions, it is still possible to detect increased expression of genes that are induced early after IFN treatment but also increased levels of genes that respond to a secondary wave of the IFN response [4]. The results show that IFN treatment significantly increases the expression of CSR31 and 32 (Fig 3A). Unlike CSR32, CSR31 was also induced with lower doses of IFN and with only 6 h of IFN treatment (Appendix Fig S3A and B). However, the levels of CSR31 and CSR32 are more than a hundred-fold lower in IFN-treated cells than in cells infected with HCV for 6 days at moi 0.3 (Fig 3A). A synergism between IFN and HCV infection was not observed as cells treated with the combination of HCV (moi 0.3 for 6 days) and IFN (10,000 U/ml during the last 3 days of infection) have CSR levels similar to those of cells that have only been infected with HCV at moi 0.3 for 6 days. Note that under these conditions, there is only a minor effect of IFN on viral replication (Appendix Fig S3C).

CSR expression could be induced in response to the activation of antiviral sensors. These sensors detect dsRNA regions of viral genomes or viral replication and induce the expression of IFN and other antiviral genes [26]. In fact, CXCL10 mRNA, used as a positive control, and several CSRs were significantly induced after transfection of HuH7 cells with the dsRNA analogue poly I:C (pIC) for 8 h, albeit at lower levels than by HCV infection (Fig 3B). However, CSR19, 21, 26, and 34 were not induced by IFN or pIC nor by infection with other viruses tested, such as influenza or Semliki Forest virus (SFV), suggesting that they could be lncRNAs that are induced specifically by HCV infection (Appendix Fig S3D).

CS32/EGOT is also induced after infection with other RNA viruses and by TLR induction

Considering all the results obtained, we decided to study CSR32, the eosinophil granule ontogeny transcript (EGOT) in more detail. EGOT was chosen because it is highly induced after infection with HCV, has poor coding potential, and accumulates preferentially in the nucleus after infection with HCV. In fact, the EGOT region of the genome has a relatively high level of histone 3 lysine 4 monomethylation over trimethylation, indicating that EGOT could be an enhancer RNA [27] (Fig EV2A). Finally, synteny alignments between different species and evaluation of the ESTs expressed in those regions suggest that EGOT has homologues in primates and rodents, which could indicate a conserved function through evolution [28].

We first determined that EGOT is a polyadenylated transcript, as increased levels of EGOT were observed in HCV-infected cells compared to non-infected controls when the RT–PCR was performed with oligo(dT) instead of random primers (Fig EV2B). RACE experiments confirmed that the sequence of EGOT expressed in HuH7 cells is properly annotated in the ENCODE and RefSeq databases except at the 5’ end, where it extends 32 additional nucleotides (Fig EV2C). EGOT cDNA was cloned and sequenced to confirm the splice junction. EGOT cDNA was transcribed in vitro and quantified. RT–PCR with serial dilutions of this RNA was performed and allowed us to...
calculate the absolute numbers of cellular EGOT, indicating that there are ~8–15 molecules of this lncRNA per cell in cells infected with HCV for 48 h. Similar experiments performed with UCA indicated that there are ~60–90 molecules of UCA1 per HuH7 cell infected with HCV for 48 h.

Then, as EGOT is induced after treatment with pIC, we speculated that it might also be induced after infection with other RNA viruses. Therefore, we evaluated EGOT levels in HuH7 cells infected for 4, 8, or 24 h with influenza virus or with SFV at a moi of 10, which caused cytopathic effects at 24 h post-infection (hpi). Infection with influenza, an RNA virus that replicates in the nucleus, and SFV, an RNA virus that replicates in the cytoplasm, induces expression of EGOT at early times post-infection (Fig 4A and B). Surprisingly, EGOT levels increased dramatically at later times post-SFV infection. As both SFV and HCV replicate in the cytoplasm and strongly induce EGOT expression, we hypothesized that cytoplasmic viral replication could be required for EGOT induction. In order to test this, we infected HuH7 cells with a moi 0.3 of HCV for 72 or 96 h. Viral replication was inhibited by treatment with a cocktail of inhibitors (sofosbuvir, daclatasvir, and ribavirin) for the last 24 or 48 h of infection, respectively. The cocktail of inhibitors did not affect EGOT levels in the absence of infection (data not shown). Inhibition of replication was confirmed by evaluation of viral RNA levels (Fig 4C, left graph). EGOT levels also decreased drastically when viral replication was inhibited (Fig 4C, right graph). Therefore, EGOT could increase in response to viral genomes or in response to any of the multiple effects caused by replication. To determine whether HCV genomes can induce EGOT, EGOT levels were evaluated in control cells, cells infected with a moi of 0.3 of HCV for 5 h (immediately after infection), cells infected with UV-treated HCV for 12 h, or cells infected with HCV for 48 h in the presence of a cocktail of inhibitors of replication. In all cases, although low levels of viral RNA were detected, EGOT expression was significantly increased compared to mock-infected cells (Fig 4D and data not shown). Finally, we evaluated whether EGOT could also increase in response to other pathogen-associated molecular patterns (PAMPs). As HuH7 cells express TLR4 (LPS sensor) and TLR7 (sensor for ssRNA and agonists like Imiquimod), cells were treated with LPS or Imiquimod for 24 h. The treatment induced CXCL10 mRNA, used as a positive control, and increased significantly the levels of EGOT (Fig 4E). Treatment of the cells with cytokines such as oncostatin or IL-6 resulted in increased levels of IL-15 receptor mRNA, used as a control, but did not alter the expression of EGOT (Fig 4E and data not shown).

**EGOT is induced by RIG-I and PKR activation in HCV-infected cells**

Collectively, our results indicate that EGOT is increased in response to different PAMPs, including pIC or the viral RNA genome. As TLR3 (pIC sensor) is poorly expressed in HuH7 cells, the cytoplasmic RIG-I could be the major sensor of pIC and viral RNA. To test whether RIG-I may mediate EGOT induction, cells transfected with siRNAs that target RIG-I (siRIG-I) were infected with HCV for 48 h. At this time, the levels of RIG-I mRNA, CXCL10 mRNA, and...
Figure 5. EGOT is induced by RIG-I and PKR through NF-κB.

A HuH7 cells were transfected with control siRNAs (siCtrl) or siRNAs that target RIG-I (siRIG-I); 48 h later, cells were infected with a moi of HCV and evaluated at 48 hpi. The relative levels of EGOT and RIG-I were evaluated by qRT–PCR in RNAs isolated from these samples. GAPDH expression was used as a reference to calculate the relative levels of each transcript. Fold increase of treated versus control cells was also calculated. Percentage versus 100% of control samples is shown.

B HuH7.S cells were mock-infected or infected with moi 0.3 of HCV for 72 h. The relative levels of EGOT mRNA were evaluated by qRT–PCR in RNAs isolated from these samples. The relative levels of EGOT and genome equivalents of HCV (CE)/μg of total RNA were also quantified by qRT–PCR. GAPDH expression was used as a reference.

C HuH7 cells were transfected with control siRNAs (siCtrl) or siRNAs that target PKR (siPKR), and 48 h later, cells were infected with a moi 0.3 of HCV and evaluated at 48 hpi. The relative levels of EGOT and PKR mRNA were evaluated by qRT–PCR in RNAs isolated from these samples. GAPDH expression was used as a reference to calculate the relative levels of each transcript. Fold increase of treated versus control cells was also calculated. Percentage versus 100% of control samples is shown.

D HuH7 cells were transfected with increasing amounts (0.03, 0.06, 0.125, 0.25, or 0.5 μg per M6 plate) of a plasmid expressing PKR (pPKR) and collected 48 h post-transfection. The relative levels of EGOT mRNA were evaluated by qRT–PCR in RNAs isolated from these samples. GAPDH expression was used as a reference. Fold increase of treated versus control cells was also calculated.

E HuH7 cells were mock-transfected (−) or transfected with 0.5 μg per M6 dish of pPKR (+), and 48 h later, cells were transfected with or without 1.0 μg of pIC or infected with a moi 0.3 of HCV. Cells were collected 8 h post-transfection with pIC or 48 hpi with HCV. The relative levels of EGOT mRNA were evaluated by qRT–PCR in RNAs isolated from these samples. GAPDH expression was used as a reference. Fold increase of treated versus control cells was also calculated.

F Schematic representation of RIG-I and PKR pathways. Indicated is PKR inhibition of translation and induction of NF-κB and activation of EGOT is also indicated.

G, H HuH7 cells were mock-transfected or transfected with plasmids expressing a dominant negative form of IRF3 (C, DNIRF3), or a superrepressor of NF-κB (H, pIKBSA). One day after transfection, cells were infected with HCV and collected at 48 hpi. The relative levels of EGOT and CXCL10 mRNA were evaluated by qRT–PCR in RNAs isolated from these samples. GAPDH expression was used as a reference to calculate the relative levels of each transcript. Fold increase of treated versus control cells was also calculated.

I Cells were treated with 20 ng/ml of TNFα for 6 or 12 h. The relative levels of EGOT mRNA were evaluated by qRT–PCR in RNAs isolated from these samples. GAPDH expression was used as a reference. Fold increase of treated versus control cells was also calculated.

Data information: The experiments were performed at least twice in triplicate (n = 6). Average values are shown and error bars indicate standard deviations. Asterisks mark significant differences (ns, nonsignificant; *P ≤ 0.05, **P ≤ 0.01, and ****P ≤ 0.0001) obtained with a two-tailed nonparametric Mann–Whitney U-test.

downstream target of RIG-I activation, and EGOT were reduced in cells expressing siRIG-I compared to control cells (Figs 5A and EV3A). To determine whether RIG-I is essential for EGOT induction, we used HuH7.5 cells, which harbor inactive RIG-I. HuH7.5 cells infected with HCV for 72 h also showed increased levels of EGOT compared to uninfected cells (Fig 5B). This indicates that another RNA sensor could be inducing EGOT. It has been reported that PKR can be activated by pIC and the HCV viral genome to induce the expression of several genes [29]. We also found more PKR phosphorylation in cells treated with pIC for 8 h or in cells infected with HCV for 48 h than in control cells, as evaluated by Western blot (Fig EV3B). Therefore, we asked whether PKR could induce EGOT expression. PKR expression was inhibited by siRNAs (siPKR) in HuH7 cells and 2 days later, cells were infected for 48 hpi with HCV. At this time point, cells expressing siPKR showed decreased PKR mRNA, decreased levels of the PKR target gene ISG15, decreased HCV replication, as has been already shown [30], and decreased levels of EGOT (Figs 5C and EV3C and D). In agreement with a role of PKR in EGOT expression, transfection of HuH7 cells with increasing concentrations of a plasmid expressing PKR resulted in increased PKR and PKR phosphorylation and in the upregulation of EGOT (Figs 5D and EV3B and E). In summary, EGOT is induced in response to pIC or HCV infection and this response is enhanced by overexpression of PKR (Fig 5E).

PKR and RIG-I induce transcription by activation of IRF3 and NF-κB (Fig 5F; [29]). To evaluate which transcription factor mediates EGOT activation, we used a dominant negative of IRF3 (DNIRF3), which lacks the DNA binding domain [31] and the NF-κB superrepressor IKB( SA), a mutated IKB at phosphorylation sites S32 and S36 that binds NF-κB but cannot be phosphorylated and degraded, and therefore hinders NF-κB activation [32]. To evaluate the functionality of DNIRF3, cells were transfected with a firefly luciferase reporter that responds to IRF3 ([PRDIII-I] 4-Luc; [33]), a plasmid expressing IRF3 and a control plasmid or the plasmid expressing DNIRF3. IKB( SA) repressor was tested in cells transfected with a luciferase reporter induced by NF-κB [NF-κB 3xLuc; [34]] and a control plasmid or the plasmid expressing IKB( SA). Then, the cells were treated with LPS for 24 h to induce NF-κB activity. A plasmid expressing Renilla luciferase was also transfected in all cases for normalization. Forty-eight hours after transfection, Renilla and firefly luciferases were quantified. As expected, normalized firefly luciferase levels were decreased in those cells expressing the inhibitors as compared to control cells (Fig EV3F and G). After this validation, plasmids expressing the inhibitors were transfected into cells, then cells were infected with HCV for 48 h, and EGOT levels were measured by qRT–PCR. Expression of the dominant negative of IRF3 decreased expression of CXCL10, used as a positive control, but did not affect EGOT levels (Fig 5G). In turn, expression of IKB( SA) decreased CXCL10 mRNA and also EGOT (Fig 5H). In agreement, EGOT also increased strongly in cells treated with TNFα, an inducer of NF-κB, for 6 or 12 h (Fig 5I). In fact, the promoter of EGOT contains binding sites for NF-κB, as identified by ChIP-Seq analysis performed by ENCODE and evaluation of conserved transcription factor binding sites deposited at UCSC (Appendix Table S3; Fig EV2).

CSR32/EGOT is also induced in the liver of HCV-infected patients

We used two independent cohorts of patients to determine that EGOT was also significantly increased in the liver of HCV-infected patients as compared to controls (Fig 6A). We did not observe differences in the levels of other CSRs, such as CSR14 or 23, between controls and HCV-infected livers (data not shown). These CSRs were taken as controls as they show good expression levels in the liver, but they are not markedly increased after HCV infection in HuH7 cells (Fig 2A, Appendix Fig S2). HCV RNA and TNFα mRNA were
also evaluated in the livers of the second cohort of patients. We observed a significant correlation between TNFα mRNA and EGOT but not between HCV RNA and EGOT (Fig 6B). This suggests that TNFα could be a major driver of EGOT expression in the liver.

Given that several CSRs have been described as oncogenes, we paid special attention to EGOT expression in patients with hepatocellular carcinoma (HCC). We observed no altered expression of EGOT in these patients as compared to HCV-infected patients without HCC (Fig 6A and data not shown). Similar results were obtained in mice. We quantified the levels of the putative mouse homologue of EGOT (mEGOT) identified by synteny [28]. We observed no differences in the expression levels of mEGOT comparing healthy mouse livers (n = 7), and peritumor (n = 17) or tumor tissue (n = 23) obtained from HCCs induced in mice 9 months after treatment with diethylnitrosamine (data not shown). In turn, the mouse homologue of PVT1 was significantly increased in tumor samples compared to healthy livers (data not shown).

EGOT allows efficient viral replication

To evaluate the role of EGOT in viral infection, we depleted EGOT from HCV-infected HuH7 cells with two independent gapmers targeting EGOT. Cells were transfected with the gapmers 1 day prior to infection with a moi 0.3 of HCV and collected at 48 hpi. The specific gapmers decreased the levels of EGOT efficiently and did not affect cell viability (Fig 7A; Appendix Fig S4). Under these conditions, viral genomes, viral titer, and viral core and NS3 proteins were significantly decreased (Fig 7B–D). Therefore, EGOT is required for efficient HCV replication.

Given that EGOT is also upregulated after infection with SFV, we evaluated the role of EGOT in SFV infection. As was done for HCV, HuH7 cells were first transfected with the gapmers targeting EGOT and controls, and then, cells were infected with a moi of 0.01 of SFV and collected at 24 hpi. The cells with decreased levels of EGOT produced fewer viral genomes and fewer SFV virions (Fig 7E–G).

Figure 5.
This indicates that EGOT expression may be required for the efficient replication of several viruses.

**EGOT is a negative regulator of the antiviral response**

EGOT is located in the genome antisense to intronic sequences of the ITPR1 gene, the inositol 1,4,5-trisphosphate receptor (Fig EV2). However, we did not observe a correlation between EGOT and ITPR1 expression, as HCV infection increases EGOT but it does not alter ITPR1 levels. To perform a stringent high-throughput analysis of correlation between the levels of EGOT and ITPR1, and to predict the function of EGOT with a high statistical confidence, we carried out a guilt-by-association genome-wide analysis [35]. To this end, we compared the expression levels of EGOT and coding genes related to cellular antiviral pathways, used as positive controls, with the expression levels of all the genes represented in a SurePrint G3 microarray. We used expression data from microarray experiments performed with 120 human samples of different origin (see Materials and Methods). Again, the results showed no significant correlation between EGOT and ITPR1 (correlation \(-0.23\)). The correlation analyses between each candidate and all the microarray genes were sorted from the genes with the highest positive correlation to those with the highest negative correlation. This matrix was used to search for GO categories with highly significant enrichment in genes that correlate positively (positive \(z\)-score) or negatively (negative \(z\)-score) with EGOT. This guilt-by-association genome-wide analysis revealed that EGOT has a highly significant negative correlation with genes that significantly enriched GO categories related to the innate immune response, including TLR signaling and the NF-κB pathway (Fig EV4). Therefore, EGOT clusters away from other genes related with the IFN pathway and the antiviral response, such as TLR3, NF-κB, IRF3, IFNAR2, or IRF1, which show a positive correlation with the antiviral pathway.

The results obtained thus far indicate that EGOT is required for efficient infection and correlates negatively with genes related to the innate immune response, suggesting that it could function by blocking antiviral responses. To test this hypothesis, we evaluated by qRT–PCR the levels of several ISGs in the HCV samples described in Fig 7, obtained from cells transfected with gapmers targeting EGOT or controls and infected with HCV for 48 h. Under these conditions, EGOT and HCV RNA levels were decreased (Fig 7A and B) while a significant increase was observed in the expression of several ISGs, including GBP1, ISG15, Mx1, BST2, ISG56, IFI6, and IFITM1 (Fig 8A and Appendix Fig S5A). No significant differences were observed in other ISGs such as IFITM2. Increased levels of ISGs were not observed when gapmers that target UCA1 were used as a control (Appendix Fig S5B). A similar increase in ISG expression was observed in non-infected cells treated with EGOT gapmers for 72 h (Fig 8B). Kinetics experiments were performed by transfecting the gapmers, infecting with HCV 24 h later and collecting the cells at 12 and 24 hpi. The results show that increased levels of GBP1 and ISG15 were observed in EGOT-depleted cells already at 12 hpi (Fig 8C and data not shown). However, at this time point there were no differences in HCV RNA levels between controls and silenced cells (Fig 8C). Decreased levels of HCV RNA were observed in EGOT-depleted cells at 24 hpi. This indicates that EGOT effect on ISGs precedes the effect on viral replication.

**Discussion**

Transcriptome analysis has allowed the identification of cellular lncRNAs induced in response to HCV infection (Fig 1 and Appendix Table S1). Out of the 35 CSRs selected, 33 were validated as upregulated after HCV infection. For further studies, we chose 10 candidates with medium-to-high expression levels that increased more than sevenfold after infection with HCV (Fig 2). We were surprised to find that several CSRs had been previously described in association with tumors. CAS15/CSR19 is a cancer susceptibility candidate with SNPs reported to be associated with clinically aggressive neuroblastoma [36]. UCA1/CSR34 and PVT1/CSR21 are well-described oncogenes upregulated in several tumors, including liver tumors, where upregulation is associated with poor prognosis [24,25,37]. It has been demonstrated that upregulation of UCA1 and PVT1 leads to increased cell proliferation. This allows us to hypothesize that the upregulation of several CSRs by HCV, including PVT-1, UCA1, and CASC15, could activate cell proliferation and several pro-carcinogenic processes that may contribute, in the long term, to the development of HCC in HCV-infected livers. Similarly, the X protein of HBV has been shown to decrease the expression of the lncRNA DREH, which functions as a tumor suppressor [38].
PVT1 expression increases the levels of myc protein, leading to increased proliferation [24]. Interestingly, PVT1 promoter responds to myc leading to a positive regulatory loop [24, 39]. Myc is also increased by NS5A after infection with HCV [40]. Therefore, HCV infection could cause a myc upregulation that increases PVT1 levels, which, in turn, increase the myc protein. Upregulation of other CSRs could also be mediated by myc or by other viral or cellular factors related to HCV infection. In agreement with this possibility, CSR19, 21, 26, or 34 are not induced by IFN, pIC or by infection with influenza or SFV (Fig 3, Appendix Fig S3). In turn, other CSRs may be induced by transcription factors involved in the synthesis of IFN and the IFN response, which are activated in response to HCV infection [13] (Fig 1C). In fact, some CSRs are induced after transfection of pIC or treatment with IFN, although the level of induction obtained with these treatments is much lower than that with HCV infection (Fig 3). In addition, the promoters of several CSRs contain binding sites for myc or IFN-related transcription factors, as identified by ChIP-Seq analysis performed by ENCODE or evaluation of conserved transcription factor binding sites deposited at UCSC [41] (Appendix Table S3).

We studied EGOT/CSR32 in more detail. EGOT is a polyadenylated noncoding RNA found, at least, in all placental mammals that contains several evolutionary conserved and thermodynamically stable secondary structures [28] (Fig EV2). EGOT is expressed during eosinophil development and in mature eosinophils where it serves to regulate the expression of toxic eosinophil proteins, such as the major basic protein and the eosinophil-derived neurotoxin [42]. Although EGOT has been described to be a lncRNA preferentially expressed in the hematopoietic system, in this study we show that EGOT expression is increased in HuH7 cells (Figs 2–5) and in the liver of patients infected with HCV (Fig 6A). We believe that this could represent increased expression in hepatocytes rather than in immune cells infiltrated in the infected liver because (i) we do not observe a significant correlation between the levels of EGOT and the levels of CD68, CD56, CD4, and CD8B mRNA markers that were used to quantify macrophages, NK cells, CD4, and CD8 T lymphocytes, respectively, and (ii) EGOT levels were very low in human PBMCs and they did not increase when PBMCs obtained from healthy donors were incubated for 8 h with IFN, LPS, or pIC (data not shown). Instead, EGOT increases markedly in HuH7 cells after infection with HCV and treatment with IFN, TLR agonists, or TNFα (Figs 2–5). Infection is detected by RIG-I and PKR, which activate NF-κB signaling and EGOT transcription (Fig 5). In agreement with this, EGOT is also upregulated after infection with other RNA viruses such as influenza virus or SFV (Fig 4A and B). Furthermore, in HuH7 cells we find a correlation between the levels of HCV RNA and the levels of EGOT (Fig 4). EGOT levels increased significantly at very early times post-infection or in cells infected with
non-replicative UV-treated HCV viruses, suggesting that EGOT may increase in response to the detection of the incoming viral genome (Fig 4D). At later times post-infection, EGOT increases substantially while inhibition of viral replication causes a similar decrease in EGOT levels (Fig 4C).

Surprisingly, we did not observe a significant correlation between HCV RNA and EGOT in the liver of patients infected with HCV (Fig 6B). Of note, it has been reported that not all hepatocytes are infected with HCV in human livers. The proportion of HCV-infected hepatocytes per patient ranges from 21 to 45%, and most infected hepatocytes express low levels of viral RNA (between 1 to 7 to 8–64 molecules depending on the study [43–45]). Instead, we find a significant correlation between the levels of TNFα mRNA and EGOT, suggesting that this cytokine could be the major driver of EGOT expression in the liver of HCV-infected patients (Fig 6B). Given the complexity of the HCV cell cycle, we hypothesize that the levels of HCV RNA in patients could reflect the influence of several factors and EGOT could be one of these factors based on the experiments performed in HuH7 cells (Fig 7A–D). Finally, our results do not support an oncogenic role of EGOT in HCC. However, a larger cohort of well-characterized patients should be evaluated to address whether the levels of EGOT correlate with patient survival or response to treatment.

Guilt-by-association studies indicated that EGOT correlates negatively with genes related to the immune response, suggesting that it could be a negative regulator of the pathway (Fig EV4). In fact, inhibition of EGOT leads to increased levels of several ISGs (Fig 8). This is observed in both HCV-infected and naive cells, where EGOT expression is very low. In this case, we hypothesize that EGOT could be expressed in a subpopulation of cells where ISG control is important. Alternatively, if EGOT is not very stable, it could be expressed transiently in most cells with time. If this is the case, EGOT may have been inhibited in many cells during the three days of the inhibition experiment. Some of the ISGs affected by EGOT repression have already been described as blocking HCV or SFV entry, replication, or release [46–51]. Therefore, it is not surprising that once EGOT silencing has led to increased levels of ISGs, a decrease of HCV or SFV replication is observed (Figs 7 and 8). However, we cannot rule out the possibility that EGOT affects viral replication in an ISG-independent manner, for instance through regulation of ITPR. Further experiments are required to understand the molecular mechanisms that allow EGOT to affect expression of some antiviral genes. In fact, the repressive role of EGOT resembles what has been recently described for the lncRNAs NRIR and NRAV [3,10]. LncCMPK2/NRIR and NRAV are negative regulators of the IFN pathway induced by IFN or by infection. In fact,
downregulation of lncCMPK2/NRIR or NRAV lncRNA activates ISG transcription and inhibits HCV or influenza replication, respectively.

EGOT is the first lncRNA described to be induced by PKR (Fig 5). PKR is a well-studied antiviral factor activated by binding of viral dsRNA molecules or pC analogues [29]. After activation, PKR inhibits translation initiation by phosphorylation of eIF2α. Many viruses, including SFV and HCV, have mechanisms that avoid the translation blockage exerted by PKR [30,52]. In fact, in the case of HCV, PKR is a proviral factor. Early after infection, HCV-activated PKR induces NF-κB and IRF3 and transcription of ISG15. ISG15 blocks the RIG-I pathway leading to decreased expression of several ISGs [29]. This favors HCV replication. Our study describes a novel pathway for PKR-mediated decrease of ISGs in HCV-infected cells. HCV-activated PKR induces NF-κB and transcription of EGOT, which decreases ISG expression (Figs 7 and 8). We hypothesize that this pathway may be relevant at later times post-HCV infection. At this time, translation initiation has been blocked by PKR activation and expression of lncRNAs, which do not require translation for functionality, may be essential to regulate the antiviral properties of the cell. Further studies will be required to elucidate the role of EGOT and other CSRs in viral infection. We believe that these studies will help to delineate the complex cellular response to infection with HCV and, probably, with other viruses and may lead to the discovery of new antivirals.

Materials and Methods

Cells, mice, and patient samples

The HuH7 and HuH7.5 cell lines, derived from a human hepatocarcinoma, were provided by Dr. Chisari’s laboratory (Scripps Research Institute, La Jolla, CA, USA). BHK cells were provided by Dr. Liljestrom’s laboratory (Karolinska Institute, Stockholm, Sweden). Human liver samples with or without HCV infection were obtained from the Biobank of the University of Navarra (Pamplona, Spain) under approval from the Ethics and Scientific Committees. Liver tissue sections were snap-frozen and stored at −80°C. The clinical data from HCV-infected subjects are shown in Appendix Table S4. Animal studies were performed following the regulations of the Animal Care Ethics Committee from the University of Navarra. Newborn (12–15 days) C57BL/6 male mice (n = 23) were treated with 25 mg/kg of diethylthiotosamine (DEN, Sigma). Seven C57BL/6 mice were used as controls. Animals were sacrificed 9 months after DEN treatment. Healthy livers from untreated animals and peritumoral and tumoral tissue from DEN-treated animals were snap-frozen and stored at −80°C.

Cell culture, fractionations, and treatments

HuH7 and HuH7.5 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen) enriched with 10% fetal bovine serum (FBS), 2 mM glutamine, 100 µg/ml streptomycin, and 100 IU/ml penicillin at 37°C in a 5% CO2 atmosphere. The hamster cell line BHK-21 (ATCC-CCL10), used for SFV production and titration, was grown with Glasgow MEM (Gibco BRL, UK) supplemented with 5% FBS, 10% tryptophate phosphate broth, 2 mM glutamine, 20 mM HEPES, 100 µg/ml streptomycin, and 100 IU/ml penicillin (BHK-21 complete medium). Cells were checked periodically for the presence of mycoplasma with the MycoAlert mycoplasma detection kit (Lonza). Cell fractionation into nucleus and cytoplasm was performed from cell pellets as described [5]. Blood was obtained from three healthy donors through the Biobank of the University of Navarra (Pamplona, Spain) under approval from the Ethics and Scientific Committees. Peripheral blood mononuclear cells (PBMCs) were selected after density gradient centrifugation using Ficoll.

PBMCs were cultured at a density of 10⁶ cells/ml in RPMI media (Gibco) and mock-treated or treated with 2,500 U/ml of IFNα (Sicor Biotech, Lithuania), 5 µg/ml of lipopolysaccharide (LPS, DIFCO), and 15 µg/ml of poly I:C (pIC, Invitrogen) for 6 h. HuH7 cells were seeded in 6-well plates 24 h before treatment. Then, they were transfected or treated with 10,000 units/ml of IFNα2 for 72 h (in all experiments except in Appendix Fig S3B, where the dose and time of IFNα are indicated in the figure legend), 20 ng/ml of TNFα for 6 or 12 h (PeproTech), 100 µg/ml of LPS for 24 h, 10 µg/ml of Imiquimod for 24 h (Invivogen), 10 µg/ml of oncostatin M (OSM) for 24 h (R&D System), or 10 ng/ml of IL-6 for 6 h (R&D System). Transfection was performed with 5 µl of Lipofectamine 2000 (Invitrogen) in 300 µl Optitemp media (Gibco). For transfection, each well plate received 10 µg of pIC, the indicated amounts of plasmids expressing PKR (cloned from pDNA1/Neo-PKR [53] by E. Nistal (CIMA, Pamplona, Spain) in positions ClaI and XhoI of pCAGGS), 0.5 µg of pIKB(SA) [32], 0.5 µg of DN-IRF3 [31], a mixture of 0.5 µg of pNF-κB-Luc (NF-κB 3xLuc; Clontech), 0.25 µg of pRL-SV40 (expressing Renilla luciferase, Promega) and 0.5 µg of pIKB(SA) or pEGFP (Promega) or a mixture of 0.5 µg of pIRF3Luc (PRDIII-I)4-Luc; [33] 0.08 µg pIRF3 (expressing IRF3, [54]), 0.25 µg of pRL-SV40, and 0.5 µg of DN-IRF3 or pEGFP. For transfections with inhibitors, 40 pmol siRNAs targeting PKR or RIG-I or 50 pmol of gamers targeting EGOT was transected per 6-well plate. siRNAs target PKR at the sequence GCAGGGAGAUAGUACUAAA [55] and RIG-I at the sequence CCGAUUAGCCGACAAUUU [56]. LNA™ longRNA GamRe oligonucleotides (EXIQON) target the sequence AGAGACCTTGAAGA (gaEGOT-1), GAGTTAGATGAAA (gaEGOT-2), or AACACGTCTATACGC (gaCtrl). UCA gamper was obtained from IONIS Pharmaceuticals. One day post-transfection, media from the cells were substituted by fresh DMEM supplemented with 10% FBS and antibiotics.

Viral infections

HCV JFH-1 was obtained from an initial viral stock from the genotype 2a JFH-1 plasmid (pJFH-1), previously described by Wakita et al [57]. The virus was amplified as described [4]. For UV inactivation, the total amount of HCV to be used was exposed to a 254-nm UV light (three cycles of 15 min) by using an uvgl-25 compact UV 4-watt lamp (UVP). Cells were infected with HCV at a moi of 0.3 for 4 h. UV-treated virus was used with a moi of 1. After 4 h of infection, viruses were removed and fresh medium was added to the cells. Cell supernatants and pellets were harvested at the indicated times post-infection. Inhibition of replication was performed with a cocktail of 500 pM daclatasvir (Med Chem Express), 1,200 pM sofosbuvir (Med Chem Express), and 100 µM ribavirin (Sigma). To inhibit ongoing replication, cells were incubated with this cocktail 48 h after infection. To inhibit replication, cells were
treated with the cocktail 24 h before infection and immediately after infection. Then, the media with the inhibitors were replaced every 48 h until the end of the experiment.

To titer infectious HCV particles, we calculated focus-forming units/ml using a modified version of a previously described protocol [58]. In brief, the supernatant of infected cells was centrifuged at 1,700 g at 4 °C for 15 min, serially diluted 10-fold in complete DMEM, and used to infect 10^5 naive HuH7 cells grown onto coverslips in 24-well plates. HCV infection was allowed to proceed for 2 days. Then, cells were fixed and permeabilized with methanol at −20°C for 15 min and used for immunofluorescence.

Influenza virus strain A/PR8/34 WT (PR8) was kindly provided by Estanislao Nistal (CIMA, Pamplona, Spain). A moi of 10 of this virus was used to infect HuH7 cells for 1 h. RNA was isolated from infected cells at the indicated times post-infection. SFV was produced by electroporating BHK cells with SFV4 in vitro-transcribed RNA as described [59]. After 24 h, SFV viral particles were purified from the cultured supernatants by ultracentrifugation for 90 min at 100,000 g through a 20% sucrose cushion. The virus pellet was resuspended in TN buffer (50 mM Tris–HCl, pH 7.4, 100 mM NaCl), quickly frozen in liquid N2, and stored at −80°C. HuH7 cells were infected with SFV for 1 h at a moi of 10 or 0.01, as indicated. To titer SFV, confluent BHK-21 cell monolayers were infected with serial dilutions of purified SFV, or cell supernatants containing SFV, diluted in infection medium (MEM containing 0.2% BSA, 2 mM glutamine, and 20 mM Hapes). After 1 h of viral adsorption, overlay medium was added (BHK-21 complete medium and Glasgow MEM-0.2% agarose, [1:1]) and cells were incubated for 72 h at 37°C. Finally, cell monolayers were fixed with 0.5% glutaraldehyde in PBS and stained with 0.1% crystal violet in methanol–H2O (20:80), and viral lysis plaques were counted in the appropriate dilution.

**Immunofluorescence, Western blot, and luciferase activity measurements**

For immunofluorescence, cells fixed on coverslips were washed three times in PBS and incubated for 2 h at 37°C with a mouse monoclonal antibody against HCV core protein (a gift from J.J. Lasarte, CIMA, Pamplona, Spain) diluted 1:500. Then, the cells were washed three times with PBS and incubated for 2 h with a secondary anti-mouse antibody conjugated with Cγ3 diluted 1:200 (Sigma). Finally, the coverslips were washed and placed on a slide glass with VECTASHIELD Mounting Medium with DAPI (Vector Labs) [60]. Cells were visualized in a fluorescence microscope (Nikon Eclipse E800). Total cells stained with DAPI and core-positive cells were counted for 72 h at 37°C. Finally, cell monolayers were fixed with 0.5% glutaraldehyde in PBS and stained with 0.1% crystal violet in methanol–H2O (20:80), and viral lysis plaques were counted in the appropriate dilution.

For Western blot analysis, cell pellets were lysed in RIPA buffer and 20 µg of protein extracts was run through a 12% acrylamide gel and transferred onto a nitrocellulose membrane (Protran Whatman) [34]. After transfer, membranes were blocked with 5% milk in TBST for 1 h and incubated with monoclonal antibodies against GAPDH diluted 1:1,000 (Sigma), HCV NS3 protein diluted 1:1,000 (anti-NS3 (JFH-1) Monoclonal Clone 2E3 Biofront), HCV core protein diluted 1:1,000 or anti-phospho-PKR diluted 1:1,000 (phospho T446 antibody E120, Abcam). After washing, membranes were incubated with a secondary anti-mouse antibody conjugated with peroxidase diluted 1:5,000 (Sigma) except for recognition of phospho-PKR, where a secondary anti-rabbit antibody conjugated with peroxidase diluted 1:10,000 (Cell Signaling) was used. Western blots were developed with ECL Plus (PerkinElmer).

Renilla and firefly luciferase activities were measured using the Dual Luciferase System (Promega) as previously described [34] in a Berthold Luminometer (Lumat LB 9507). The values obtained for firefly luciferase were corrected for equal transfection efficiency with Renilla luciferase activity.

**RNA extraction, RT–PCR, and cloning**

Human and mouse tissue was homogenized using the ULTRA-TURRAX dispersing machine (t25 basic IKK-WERKE) [61], and RNA was isolated as described [62]. DNase (Fermentas) treatment was performed to eliminate DNA from the samples. RNA from cell pellets was extracted with the MaxWell 16 research system from Promega following the manufacturer’s recommendations. RNA concentration was measured using NanoDrop 1000 Spectrophotometer. The quality of the RNA was analyzed by Bioanalyzer (Agilent Technologies). Reverse transcription (RT) was performed as described [62]. An oligoDT primer (T<sub>40</sub>) was used in the RT reaction to determine whether EGOT is polyadenylated. Those candidates located in regions with transcription in the sense and antisense orientation were also evaluated with strand-specific PCR.

The quantitative RT–PCR (qRT–PCR) was performed in the C1000 Touch Thermal Cycler from Bio-Rad. The samples were incubated at 37°C for 60 min, then at 95°C for 60 s and then immediately cooled to 4°C. qPCR was performed in the CFX96 Real-Time System from Bio-Rad as described [63]. The results were analyzed with Bio-Rad CFX Manager software. GAPDH levels were evaluated in all the cases as a reference. Only samples with similar GAPDH amplification were analyzed further. To calculate the relative RNA levels, \( \frac{C\text{t treated}}{C\text{t untreated}} \) was used, where \( \Delta C\text{t} \) is the gene of interest – \( C\text{t} \) of the GAPDH mRNA internal control. The primers used are listed in Appendix Table S5 and were designed with the Primer3 program (http://frodo.wi.mit.edu).

EGOT RACE was performed with the 5’ and 3’RACE systems for rapid amplification of cDNA ends (Thermo Fisher) using the conditions recommended by the supplier and RNA extracted from HuH7 cells infected with HCV for 48 h. Amplified products were resolved in agarose gels and evaluated by sequencing. Similar PCR conditions were used to amplify EGOT with Thermo Scientific Phusion High-Fidelity DNA Polymerase (Thermo Fisher). Primers used were cEGOT forward and reverse (Appendix Table S5). The amplified product was digested with XhoI and BglII and cloned into the same sites of pCAGGS to obtain pCAGGS-EGOT. Positive clones were verified by sequencing to confirm that the exon junction and EGOT sequence are identical to what has been annotated in several public databases (ENCODE, RefSeq, and ENSEMBL). pCAGGS-EGOT was then digested with Smal and BglII and cloned into the same sites of pSuper to obtain pSuper-EGOT, which positions EGOT under a T7 promoter.

pSuper-EGOT was digested with Clal and used in an in vitro transcription reaction with T7 (Promega) as described previously.
[64]. Then, DNA was digested with RNase-free DNase (Promega) and RNA was quantified by bioanalyzer. Five nanograms of RNA was retrotranscribed as described, and serial dilutions 1:10 were used as a standard for a qPCR. The levels of EGOT in HCV-infected HuH7 cells and controls were evaluated in parallel, and absolute quantification was performed. Similarly, the levels of HCV RNA were determined in parallel with serial dilutions of a plasmid containing the HCV JFH-1 cDNA, which were used as a standard in the qPCR and allowed the calculation of HCV RNA genome equivalents (GE)/µg of total RNA as has been previously described [58].

Microarray hybridization and high-throughput sequencing

RNA of excellent quality, as determined by Bioanalyzer (Agilent Technologies), was hybridized to microarrays or used for high-throughput sequencing. For microarray hybridization, the samples were processed using manufacturer protocols and hybridized to the Agilent SurePrint G3 Human Gene Expression 8×60K microarray. Microarray data normalization was performed using the quantile algorithm and analyzed as described [65]. For RNASeq, RNA was treated with the Ribo-Zero rRNA removal kit (Epicenter) to deplete ribosomal RNA. Library preparation with the TruSeq RNA sample preparation kit (Illumina) and sequencing was performed at the EMBL genomics core facility (Genecore) in an Illumina HiSeq 2000. Sequences were paired-end, 105 bases long, and strand specific. RNASeq data analysis was performed as described [5]. Further analysis and graphical representations were performed using an R/Bioconductor [66]. The biological knowledge extraction was complemented through the use of Ingenuity Pathway Analysis (Ingenuity Systems, www.ingenuity.com). All transcriptome data are available at the NCBI Gene Expression Omnibus (GEO) data repository (http://www.ncbi.nlm.nih.gov/geo).

Bioinformatic analysis

Reads from all the differentially expressed genomic regions were visualized in the Integrative Genomics Viewer (IGV) (www.broadinstitute.org/igv), the sequences were compared to the ENSEMBL and ENCODE databases, and more information was searched for in the Genome Browser from UCSC (http://genome.ucsc.edu) [67,68]. Candidates were divided into coding, noncoding (according to UCSC classification), or non-annotated, when the transcription of the sequence had not been annotated in the databases. ORF Finder (NCBI) was used to evaluate the length of all probable ORFs in the evaluated transcripts. Coding potential was assayed with Phylogenetic Codon Substitution Frequencies (PhyloCSF) [20,23], the coding potential assessment tool (CPAT) [22], and by searching the LNCipedia database [20]. PhyloCSF uses multiple alignments to calculate the phylogenetic conservation score and determines whether a multispecies nucleotide sequence alignment is likely to represent a protein-coding region [23]. CPAT uses a model built with open reading frame size and coverage together with codon (Ficket score) and hexamer (hexamer score) usage bias to calculate a coding probability value. Human noncoding transcripts have a coding probability value lower than 0.364, used as a threshold with the highest sensitivity and specificity [22]. The LNCipedia database evaluates the presence of transcripts in the PRIDE Archive, a database for proteomic data, or in the Lee or Bazzini lists of transcripts associated with ribosomes in ribosome profiling experiments [18,19,21].

The Illumina Human BodyMap (HBM) dataset was downloaded from SRA database and processed using the following pipeline: (i) The preprocessing of reads included elimination of contaminating adapter substrings was performed with Scythe (https://github.com/vsbuffalo/scythe) and the quality-based trimming was done using Sickle (https://github.com/najoshi/sickle); (ii) the alignment of reads to the human genome (hg19) was performed using TopHat2 mapper; and (iii) the quantification of the 37 CSRs using the FPKM (fragments per kilobase of transcript per million fragments mapped) was carried out with Cuffquant.

To perform the guilt-by-association analysis [35], we collected data from 120 samples hybridized to SurePrint G3 microarrays. These samples included the 6 RNA samples isolated from HuH7 cells infected or not with HCV, and 114 RNAs obtained from human samples of different origin, including healthy cells and tissues (one sample from CD34 cells, 15 colon samples, 8 rectum samples, and 3 peripheral blood samples), tumors (20 colon cancers (GSE46271), 8 rectal cancers, 9 colon metastases, 3 acute lymphoblastic leukemias from B cells and one from T cells), cell lines (7 MOLT4, 1 Tera, 10 TOM1, one DLD1, one LS513, one HT29, one SW620), cell line-derived cancer stem cells (one derived from DLD1, one from LS513, one from HT29, and one from SW620), stem cells (3 adipose-derived stem cells, 6 IPS cells derived from fibroblasts, and 2 derived from CD34 cells), and 6 samples of HuH7 cells treated with IFN (GSE64794). Then, a Pearson correlation analysis was performed between CSR32 and all the genes represented in the SurePrint G3 Human microarray. Coding genes related to cellular antiviral pathways were randomly selected and included in the analysis as positive controls. The obtained correlation matrix was used as input for giTools [69] where an enrichment analysis of GO categories was performed using z-score and FDR [70].

Statistical analysis

Statistical analysis was performed using GraphPad. Statistical significance of treated or infected versus non-treated or non-infected samples was calculated using a two-tailed nonparametric Mann–Whitney U-test for samples that do not follow a normal distribution. When the samples followed a normal distribution according to the Shapiro–Wilk test, a two-tailed Student’s t-test was used. Correlation was assessed by Spearman’s correlation coefficients. All data show means ± standard deviation. P-values lower than 0.05 were deemed as significant. In all data shown, * denotes P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001.

Expanded View for this article is available online.

Acknowledgements

We thank Nerea Razquin and Erkuden Casales for excellent technical assistance, Paul Miller for editorial work, and Estanislao Nistal and Rafael Aldabe for influenza and HCV, respectively. We also thank Estanislao Nistal for the plasmid expressing PKR, DN-IRF3, IRF3, and IκB(SA), Esther Larrea for IFNxa2, LPS, IL-6, and oncostatin, Stephan Ludwig for (PRDII-Δ)4-Luc, Pablo Sarobe for Imiquimod, Juanjo Lasante for the antibody against HCV core protein, Lulu Huang, from IONIS Pharmaceuticals, for UCA gapmers, Sandra Herbás for
PBMCs, Celia Perales for help with the HCV replication inhibitors, and Marta Ruiz-Guillen for providing purified SFV. We would like to thank patients for the generous donation of samples and Virginia Villar and the biobank of the University of Navarra for their mediation. This work was supported by grants from the Ministry of Economy (SAF2012-40003, BFU2013-50517-EXP, SAF2015-70971-R), grant Ortiz de Landazuri from the Government of Navarra, Fundacion San Millan de la Cogolla (CS12011-31-32), Caja Navarra Foundation (70020), European FEDER funding and by the project RNAREG (CSD2009-00080), funded by the Ministry of Science and Innovation under the program CONSOLIDER INGENIO 2010. MB is the recipient of a FPI fellowship.

Author contributions
EC performed initial analysis and validation of CSRs and together with MB and CP, the analysis of EGOT functionality; VS was in charge of all the bioinformatics analysis except the guilt-by-association studies that were carried out by EG; CS performed all experiments related to SFV and PG experiments with replication inhibitors; JPU was in charge of the RACE experiments, ME obtained and analyzed mouse samples, and PF conceived the project and the analysis of EGOT functionality; VS was in charge of all the bioinformatics analysis except the guilt-by-association studies that were carried out by EG; CS performed all experiments related to SFV and PG experiments with replication inhibitors; JPU was in charge of the RACE experiments, ME obtained and analyzed mouse samples, and PF conceived the project and the required experiments, provided the budget, led the team in the analysis and interpretation of the data, and wrote the manuscript.

Conflict of interest
The authors declare that they have no conflict of interest.

References

© 2016 The Authors
EMBO reports Vol 17 | No 7 | 2016
1027